Vir Biotechnology logo
Vir Biotechnology
VIR | NASDAQ
Chart Builder DCF Calculator
$9.58
-$0.38 (-3.82%)
At close: Nov 16, 2026, 4:00 PM ET
$9.59
+$0.01 (+0.10%)
After-hours: Nov 16, 2026, 7:55 PM ET

Vir Biotechnology Company Profile

Company profile explained

Company Profile

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

Key Executives

Name Position
Marianne De Backer President, CEO & Director
Aziz Sawaf Executive VP, CFO & Principal Financial Officer
Brent Sabatini Senior Vice President, Principal Accounting Officer & Chief Accounting Officer
Carolyn Wang Senior Vice President of Corporate Communications
Jeff Calcagno Executive Vice President & Chief Business Officer
Jennifer Eileen Towne Executive Vice President & Chief Scientific Officer
Kiki Patel Head of Investor Relations
Lawrence Corey Co-Founder & Scientific Advisor
Louis J. Picker Co-Founder & Scientific Advisor
Maninder Hora Executive Vice President & Chief Technical Operations Officer
Toby Medaris Executive Vice President & Chief Human Resources Officer
Vanina De Verneuil Executive Vice President, General Counsel & Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 28, 2026 4 Filing
Oct 28, 2026 3 Filing
Oct 28, 2026 8-K Current Report
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 14, 2026 8-K Current Report
Oct 08, 2026 8-K Current Report
Oct 06, 2026 3 Filing
Oct 01, 2026 8-K Current Report
Aug 12, 2026 4 Filing
Aug 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Vir Biotechnology
Vir Biotechnology logo
Country United States
IPO Date Oct 11, 2019
Industry Biotechnology
Sector Healthcare
Employees 367
CEO Marianne De Backer

Contact Details

499 Illinois Street San Francisco, California 94158 United States

Stock Details

Ticker Symbol VIR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001706431
CUSIP Number 92764N102
ISIN Number US92764N1028
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.